Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Diabetes

• Publication date

  2002-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/diabetes.51.3.808PMID 11872684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Echocardiographic load-independent indices of contractility in children and adolescents with type I diabetes: Effect of metabolic control and insulin on left ventricular performance

  2006cited by this paper
• Comparison of myocardial blood flow during dobutamine-atropine infusion with that after dipyridamole administration in normal men.

  2001cited by this paper
• Cardiovascular effects of sulphonylureas: role of KATP channels

  2000cited by this paper
• Myocardial K(ATP) channels in preconditioning.

  2000cited by this paper
• Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation.

  2000cited by this paper
• Effect of plasma insulin level on myocardial blood flow and its mechanism of action.

  2000cited by this paper
• Insulin improves functional and metabolic recovery of reperfused working rat heart.

  1999cited by this paper
• Coronary flow reserve in young men with familial combined hyperlipidemia.

  1999cited by this paper
• Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

  1999cited by this paper
• Early impairment of coronary flow reserve in young men with borderline hypertension.

  1998cited by this paper
• Energy metabolism after ischemic preconditioning in streptozotocin-induced diabetic rat hearts.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Hyperglycemia Rather Than Insulin Resistance Is Related to Reduced Coronary Flow Reserve in NIDDM

  1998cited by this paper
• Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.

  1997cited by this paper
• Dobutamine positron emission tomography: absolute quantitation of rest and dobutamine myocardial blood flow and correlation with cardiac work and percent diameter stenosis in patients with and without coronary artery disease.

  1996cited by this paper
• Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration.

  1996cited by this paper
• Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.

  1996cited by this paper
• Improvement in ischemic parameters during repeated exercise testing: a possible model for myocardial preconditioning.

  1996cited by this paper
• Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty.

  1995cited by this paper
• Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs.

  1995cited by this paper
• Dobutamine stress: effects on regional myocardial blood flow and wall motion.

  1995cited by this paper
• ATP-sensitive potassium channels and myocardial preconditioning

  1995cited by this paper
• Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.

  1994cited by this paper
• Does ischemic preconditioning occur in patients?

  1994cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper
• Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects

  1993cited by this paper
• Assessment of the effects of dobutamine on myocardial blood flow and oxidative metabolism in normal human subjects using nitrogen-13 ammonia and carbon-11 acetate.

  1993cited by this paper
• Nuclear cardiology : state of the art and future directions

  1993cited by this paper
• Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.

  1993cited by this paper
• The sulfonylurea receptor.

  1992cited by this paper
• Predictors of Early Morbidity and Mortality After Thrombolytic Therapy of Acute Myocardial Infarction: Analyses of Patient Subgroups in the Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase II

  1992cited by this paper
• The Diabetic Heart

  1991cited by this paper
• Comparison of coronary vasodilation with intravenous dipyridamole and adenosine.

  1991cited by this paper
• Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.

  1990cited by this paper
• Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease.

  1990cited by this paper
• Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

  1989cited by this paper
• Oral hypoglycemic agents.

  1989cited by this paper
• Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry.

  1988cited by this paper
• Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.

  1986cited by this paper
• Cross-sectional Echocardiography: II. Analysis of Mathematic Models for Quantifying Volume of the Formalin-fixed Left Ventricle

  1980cited by this paper
• Cross‐sectional Echocardiography 1. Analysis of Mathematic Models for Quantifying Mass of the Left Ventricle in Dogs

  1979cited by this paper

• Impaired fasting glucose and sulfonylureas increased the risk of major cardiovascular events in patients with inflammatory arthritis

  2025cites this paper
• Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs

  2022cites this paper
• Effects of glucose‐lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: An updated meta‐analysis of randomized controlled trials with external adjudication of events

  2022cites this paper
• Glucose-lowering therapy in patients undergoing percutaneous coronary intervention.

  2021cites this paper
• Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease

  2021cites this paper
• Effects of antidiabetic drugs on left ventricular function/dysfunction: a systematic review and network meta-analysis

  2020cites this paper
• A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas?

  2020cites this paper
• Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials.

  2020cites this paper
• Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update

  2020cites this paper
• Mesa 3: Efectos cardiovasculares de fármacos antidiabéticos

  2020cites this paper
• Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial

  2019cites this paper
• Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature

  2019cites this paper
• Mechanisms of cardiovascular protection of non-insulin antidiabetic medications

  2018cites this paper
• Effect of glucose-lowering therapies on heart failure

  2018cites this paper
• Glycogen synthase kinase-3 b mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore

  2018cites this paper
• Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

  2017cites this paper
• Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta‐analysis of survival data

  2017cites this paper
• Cardiovascular events associated with second‐line anti‐diabetes treatments: analysis of real‐world Korean data

  2017cites this paper
• Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

  2017cites this paper
• Cardiovascular effects of anti-diabetes drugs

  2016cites this paper
• DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.

  2016cites this paper
• Cardiovascular events and all-cause mortality associated with sulfonylureas compared to other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data

  2016cites this paper
• Dipeptidyl Peptidase-4 Inhibitors and Heart Failure: Friends or Foes?

  2015cites this paper
• Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women

  2014cites this paper
• Frequency and factors associated with insulin therapy in type 2 diabetics in Granma Province

  2014cites this paper
• The path to approval of new drugs for diabetes

  2013cites this paper
• Clinical Trials to Clinical Practice : Role of Sulfonylureas in Today ’ s Practice

  2013cites this paper
• Sulfonylureas and meglitinides: historical and contemporary issues.

  2013cites this paper
• Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials

  2013cites this paper
• Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

  2012cites this paper
• Treating diabetes today with gliclazide MR: a matter of numbers

  2012cites this paper
• The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus

  2012cites this paper
• Estudo da proteção renal com propofol e o isoflurano durante a esquemia e a reperfusão, com hiperglicemia transitória

  2011cites this paper
• CARDIOPROTECTION BY VOLATILE ANESTHETICS: FROM BENCH TO BEDSIDE AND BACK

  2011cites this paper
• Perioperative myocardial protection

  2009cites this paper
• Effect of 1-[4-[2-(4-Bromobenzenesulfonamino)ethyl]phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a New Synthetic Sulfonylurea Compound, on Glucose Metabolism in vivo and in vitro

  2009cites this paper
• Consequences of Delaying Progression to Optimal Therapy in Patients with Type 2 Diabetes Not Achieving Glycemic Goals

  2009cites this paper
• Glimepiride upregulates eNOS activity and inhibits cytokine‐induced NF‐κB activation through a phosphoinoside 3‐kinase–Akt‐dependent pathway

  2009cites this paper
• [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].

  2009cites this paper
• Endogenous Activation of Mitochondrial KATP Channels Protects Human Failing Myocardium From Hydroxyl Radical–Induced Stunning

  2009cites this paper
• Il trattamento farmacologico del diabete di tipo 2 e la prevenzione cardiovascolare: cosa aggiunge liraglutide?

  2009cites this paper
• Clinical cardioprotection and the value of conditioning responses.

  2009cites this paper
• Why to screen heart disease in diabetes.

  2009cites this paper
• Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease.

  2008cites this paper
• Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?

  2008cites this paper
• Inhalational anaesthetics and cardioprotection.

  2008cites this paper
• Oral Glyburide, But Not Glimepiride, Blocks the Infarct-Size Limiting Effects of Pioglitazone

  2008cites this paper
• Treatment of Type 2 Diabetes With Combined Therapy

  2008cites this paper
• Sulfonilureas en el tratamiento del paciente con diabetes mellitus tipo 2

  2008cites this paper
• Pioglitazone and sulfonylureas: effectively treating type 2 diabetes

  2007cites this paper
• Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning

  2007cites this paper
• Efeitos da glibenclamida na função e histologia renais, em ratos submetidos à hemorragia aguda sob anestesia com sevoflurano

  2007cites this paper
• Adenosine in health and disease. A human in vivo study on genetic, metabolic, and pharmacological determinants of the cardiovascular effects of adenosine.

  2007cites this paper
• The Place of Insulin Secretagogues in the Treatment of Type 2 Diabetes in the Twenty-First Century

  2007cites this paper
• Diabetes and the heart: could the diabetic myocardium be protected by preconditioning?

  2007cites this paper
• (R)-ACX, a pancreatic beta-cell selective sulfonylurea, does not aggravate myocardial ischemia-reperfusion damage.

  2007cites this paper
• Pharmacotherapy of Diabetes

  2007cites this paper
• Sulphonylureas and cardiovascular risk: facts and controversies

  2006cites this paper
• Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

  2006cites this paper
• Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery.

  2006cites this paper
• Do sulfonylurea drugs increase the risk of cardiac events?

  2006cites this paper
• The place of sulfonylureas in the therapy for type 2 diabetes mellitus.

  2006cites this paper
• ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases

  2006cites this paper
• Review: Sulphonylureas and cardiovascular risk: facts and controversies

  2006cites this paper
• Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors.

  2005cites this paper
• Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry

  2005cites this paper
• Dehydroepiandrosterone administration in humans: evidence based?

  2005cites this paper
• ATP-sensitive potassium channels.

  2005cites this paper
• [Therapy with oral antidiabetic agents -- special considerations in the case of coronary heart disease].

  2005cites this paper
• The concept of anaesthetic-induced cardioprotection: mechanisms of action.

  2005cites this paper
• Diabetes and cardiovascular disease: the road to cardioprotection

  2005cites this paper
• Orale Antidiabetika heute - Substanzen, Indikationen, Perspektiven

  2005cites this paper
• Therapie mit oralen Antidiabetika - Besonderheiten bei koronarer Herzerkrankung

  2005cites this paper
• Sulfonamide chalcone as a new class of α-glucosidase inhibitors

  2005cites this paper
• The effect of anaesthetics on the myocardium--new insights into myocardial protection.

  2005cites this paper
• Diabetes mellitus and its treatment

  2005cites this paper
• Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore

  2004cites this paper
• Role of clinical pathologies in myocardial injury following ischaemia and reperfusion.

  2004cites this paper
• Ischaemic preconditioning: from molecular characterisation to clinical application--part II.

  2004cites this paper
• Type 2 diabetes mellitus: what is the optimal treatment regimen?

  2004cites this paper
• Overview of the various in vitro and in vivo models of ischaemic preconditioning in humans with main endpoints and limitations

  2004cites this paper
• In-hospital management of type 2 diabetes mellitus.

  2004cites this paper
• Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.

  2004cites this paper
• WHAT SHOULD THE ANAESTHETIST KNOW ABOUT ISCHAEMIA-REPERFUSION INJURY? 4RC1

  2004cites this paper
• An overview of the role of insulin in the treatment of hyperglycemia during acute myocardial ischemia.

  2004cites this paper
• Secretagogues and Cardiac Risk

  2004cites this paper
• The UGDP Controversy: thirty-four years of contentious ambiguity laid to rest

  2004cites this paper
• The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.

  2004cites this paper
• Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore.

  2004cites this paper
• Sulfonylureas: Basic Aspects and Clinical Uses

  2004cites this paper
• Effects of oral amino acid supplementation on myocardial function in patients with type 2 diabetes mellitus.

  2004cites this paper
• The UGDP Story The UGDP was the brainchild of Max Miller of Case Western Reserve

  2004cites this paper
• Reduction of cardiovascular morbidity and mortality in Type 2 diabetes. A rational approach to hypoglycemic therapy

  2004cites this paper
• Management of diabetes and hyperglycemia in hospitals.

  2004cites this paper
• Early myocardial dysfunction in the diabetic heart: current research and clinical applications.

  2004cites this paper
• CARDIOPROTECTION BY VOLATILE ANAESTHETICS: ANAESTHETIC-INDUCED PRECONDITIONING

  2004cites this paper
• Ischaemic preconditioning: from molecular characterisation to clinical application--part I.

  2004cites this paper
• All‐cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides

  2004cites this paper
• Hyperglycaemia in diabetes: impact on nephropathy and cardiac risk.

  2003cites this paper
• Anaesthetics and cardiac preconditioning. Part II. Clinical implications.

  2003cites this paper